Cargando…

CRAF R391W is a melanoma driver oncogene

Approximately 75% of melanomas have known driver oncogenic mutations in BRAF, NRAS, GNA11 or GNAQ, while the mutations providing constitutive oncogenic signaling in the remaining melanomas are not known. We established a melanoma cell line from a tumor with none of the common driver mutations. This...

Descripción completa

Detalles Bibliográficos
Autores principales:	Atefi, Mohammad, Titz, Bjoern, Tsoi, Jennifer, Avramis, Earl, Le, Allison, Ng, Charles, Lomova, Anastasia, Lassen, Amanda, Friedman, Michael, Chmielowski, Bartosz, Ribas, Antoni, Graeber, Thomas G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4897636/ https://www.ncbi.nlm.nih.gov/pubmed/27273450 http://dx.doi.org/10.1038/srep27454

Ejemplares similares

Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma
por: Atefi, Mohammad, et al.
Publicado: (2015)

Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma
por: Wong, Deborah JL, et al.
Publicado: (2014)

Erratum to: Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma
por: Wong, Deborah JL, et al.
Publicado: (2015)

JUN dependency in distinct early and late BRAF inhibition adaptation states of melanoma
por: Titz, Bjoern, et al.
Publicado: (2016)

Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
por: Heidorn, Sonja J., et al.
Publicado: (2010)

Oncogenic RAS drives the CRAF‐dependent extracellular vesicle uptake mechanism coupled with metastasis
por: Choi, Dongsic, et al.
Publicado: (2021)

Selective CRAF Inhibition Elicits Transactivation
por: Morgan, Charles W., et al.
Publicado: (2021)

Registered report: Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF
por: Bhargava, Ajay, et al.
Publicado: (2016)

Characterization of Postinfusion Phenotypic Differences in Fresh Versus Cryopreserved TCR Engineered Adoptive Cell Therapy Products
por: Nowicki, Theodore S., et al.
Publicado: (2018)

CRAF mutations in lung cancer can be oncogenic and predict sensitivity to combined type II RAF and MEK inhibition
por: Noeparast, Amir, et al.
Publicado: (2019)

Natural Killer T Cells in Advanced Melanoma Patients Treated with Tremelimumab
por: Ibarrondo, F. Javier, et al.
Publicado: (2013)

A MEK-independent role for CRAF in mitosis and tumor progression
por: Mielgo, Ainhoa, et al.
Publicado: (2011)

PET imaging to non-invasively study immune activation leading to antitumor responses with a 4-1BB agonistic antibody
por: Escuin-Ordinas, Helena, et al.
Publicado: (2013)

Optogenetically controlled RAF to characterize BRAF and CRAF protein kinase inhibitors
por: Chatelle, Claire V., et al.
Publicado: (2016)

Three distinct regions of cRaf kinase domain interact with membrane
por: Prakash, Priyanka, et al.
Publicado: (2019)

S391 The domestic animal revolution and infiuenza
por: Olsen, B.
Publicado: (2007)

SAR Probing of KX2-391 Provided Analogues With Juxtaposed Activity Profile Against Major Oncogenic Kinases
por: Omar, Abdelsattar M., et al.
Publicado: (2022)

Kinase-independent role for CRAF-driving tumour radioresistance via CHK2
por: Advani, Sunil J., et al.
Publicado: (2015)

Impaired neuronal maturation of hippocampal neural progenitor cells in mice lacking CRAF
por: Pfeiffer, Verena, et al.
Publicado: (2018)

Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma
por: Lassen, Amanda, et al.
Publicado: (2014)

Abstract: Congenital Syndactyly Reconstruction of 391 Webspaces
por: Colen, David, et al.
Publicado: (2016)

Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway
por: Atefi, Mohammad, et al.
Publicado: (2011)

Characterization of In Vivo Keratin 19 Phosphorylation on Tyrosine-391
por: Zhou, Qin, et al.
Publicado: (2010)

Targeting the prohibitin scaffold-CRAF kinase interaction in RAS-ERK-driven pancreatic ductal adenocarcinoma
por: Luan, Zhou, et al.
Publicado: (2014)

Erianin suppresses constitutive activation of MAPK signaling pathway by inhibition of CRAF and MEK1/2
por: Wang, Penglei, et al.
Publicado: (2023)

CroS(R391), an ortholog of the λ Cro repressor, plays a major role in suppressing polV(R391)‐dependent mutagenesis
por: McDonald, John P., et al.
Publicado: (2021)

Phosphoproteomic Analysis of Platelets Activated by Pro-Thrombotic Oxidized Phospholipids and Thrombin
por: Zimman, Alejandro, et al.
Publicado: (2014)

ROSAT PSPC observation of the supernova remnant 3C391
por: Rho, J, et al.
Publicado: (1996)

PM391. THE USE OF AMISULPRIDE IN TREATMENT OF PATIENTS WITH RESIDUAL SCHIZOPHRENIA
por: Janjic, Vladimir, et al.
Publicado: (2016)

391. Evaluation of Second-Generation Triazoles in the Treatment of Refractory Coccidioidomycosis
por: Yoon, Janet, et al.
Publicado: (2018)

SUN-391 Denosumab Treatment of Patients with Osteoporosis and Idiopathic Hypercalciuria
por: Chu, Winston S, et al.
Publicado: (2020)

Oncogenic drivers and mitochondrial dependency
por: Alvarez-Calderon, Francesca, et al.
Publicado: (2015)

X-linked Inhibitor of Apoptosis Protein negatively regulates neuronal differentiation through interaction with cRAF and Trk
por: Fadó, Rut, et al.
Publicado: (2013)

A CRAF/glutathione-S-transferase P1 complex sustains autocrine growth of cancers with KRAS and BRAF mutations
por: Niitsu, Yoshiro, et al.
Publicado: (2020)

Implications of glutathione-S transferase P1 in MAPK signaling as a CRAF chaperone: In memory of Dr. Irving Listowsky
por: NIITSU, Yoshiro, et al.
Publicado: (2022)

Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition
por: Mok, Stephen, et al.
Publicado: (2015)

391. Outcomes of Empiric Antimicrobial Therapy in COVID-19 Positive Patients
por: Medler, Corey J, et al.
Publicado: (2020)

Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines
por: von Euw, Erika, et al.
Publicado: (2012)

Oncogenic driver mutations in lung cancer
por: Luo, Susan Y, et al.
Publicado: (2013)

Combined Targeting of BRAF and CRAF or BRAF and PI3K Effector Pathways Is Required for Efficacy in NRAS Mutant Tumors
por: Jaiswal, Bijay S., et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_bic1t8bqo50a6c920ctrqrb0hg